Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China
From an economic standpoint, GEMNABP represents the favored choice in the prevailing market conditions among these three first-line combination chemotherapy regimens. The price simulation of liposomal irinotecan conducted in this study could provide valuable evidence for healthcare decision-making. Further evidence regarding the budget impact is still needed.
Authors
- Zhengxiong Li (ORCID: https://orcid.org/0000-0003-1880-5096)
- Yong Pan (ORCID: https://orcid.org/0000-0001-9033-719X)
- Yingzhou Fu
- Ling Ma (ORCID: https://orcid.org/0000-0002-0430-0807)
- Zuojuan Xiang
Institutions
- Kunming University of Science and Technology (CN)
- Central South University (CN)
- Xuzhou Medical College (CN)
- First People's Hospital of Yunnan Province (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3389/fphar.2024.1488645
- Citations
- 4
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.13